PSA and other tissue kallikreins for prostate cancer detection

European Journal of Cancer

Volumn 43, Issue 13, 2007, Pages 1918-1926

  Stephan, Carsten ^a   Jung, Klaus ^a   Lein, Michael ^a   Diamandis, Eleftherios P ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cancer detection; kallikreins; Prostate cancer; Prostate specific antigen; Serine proteases; Tumour markers

Indexed keywords

KALLIKREIN; KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; DATA ANALYSIS; FOOD AND DRUG ADMINISTRATION; HUMAN; LABORATORY TEST; MEDICAL RESEARCH; MULTIGENE FAMILY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN LOCALIZATION;

BIOPSY, NEEDLE; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TISSUE KALLIKREINS;

EID: 34548066226     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.06.006     Document Type: Article

References (139)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Oberaigner W., Horninger W., Klocker H., Schonitzer D., Stuhlinger W., and Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 164 (2006) 376-384
3. Concato J., Wells C.K., Horwitz R.I., et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 166 (2006) 38-43
4. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293-306
5. Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. Purification of a human prostate specific antigen. Invest Urol 17 (1979) 159-163
6. Papsidero L.D., Wang M.C., Valenzuela L.A., Murphy G.P., and Chu T.M. A prostate antigen in sera of prostatic cancer patients. Cancer Res 40 (1980) 2428-2432
7. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56 (2000) 255-260
8. Nixon R.G., and Brawer M.K. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol 79 Suppl 1 (1997) 61-67
9. Soletormos G., Semjonow A., Sibley P.E., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51 (2005) 1342-1351
10. Singh R., Cahill D., Popert R., and O'Brien T.S. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int 92 (2003) 932-935
11. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37 (1991) 1618-1625
12. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222-226
13. Christensson A., Björk T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 (1993) 100-105
14. Zhang W.M., Finne P., Leinonen J., et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 44 (1998) 2471-2479
15. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., and Stenman U.H. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 45 (1999) 814-821
16. Lilja H., Haese A., Björk T., et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 162 (1999) 2029-2034
17. Brawer M.K., Meyer G.E., Letran J.L., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52 (1998) 372-378
18. Brawer M.K., Cheli C.D., Neaman I.E., et al. Complexed prostate specific prostate antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163 (2000) 1476-1480
19. Mitchell I.D.C., Croal B.L., Dickie A., Cohen N.P., and Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 162 (2001) 1549-1553
20. Stephan C., Jung K., Lein M., Sinha P., Schnorr D., and Loening S.A. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 1133-1147
21. Mikolajczyk S.D., Grauer L.S., Millar L.S., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 (1997) 710-714
22. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
23. Steuber T., Nurmikko P., Haese A., et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 168 (2002) 1917-1922
24. Stenman U.H., Leinonen J., Zhang W.M., and Finne P. Prostate-specific antigen. Semin Cancer Biol 9 (1999) 83-93
25. Leinonen J., Zhang W.M., and Stenman U.H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 155 (1996) 1099-1103
26. Stenman U.H., Finne P., Zhang W.M., and Leinonen J. Prostate-specific antigen and other prostate cancer markers. Urology 56 (2000) 893-898
27. Jung K., Brux B., Lein M., et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin Chem 46 (2000) 47-54
28. Ornstein D.K., Englert C., Gillespie J.W., et al. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. Clin Cancer Res 6 (2000) 353-356
29. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (1995) 1214-1220
30. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
31. Jung K., Stephan C., Lein M., et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42 (1996) 1026-1033
32. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N., Gasior G.H., and Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (1996) 55-61
33. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
34. Catalona W.J., Partin A.W., Finlay J.A., et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 (1999) 220-224
35. Uemura H., Nakamura M., Hasumi H., et al. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy. Int J Urol 11 (2004) 494-500
36. Mettlin C., Chesley A.E., Murphy G.P., et al. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39 (1999) 153-158
37. Tornblom M., Norming U., Becker C., Lilja H., and Gustafsson O. Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level. BJU Int 87 (2001) 638-642
38. Stephan C., Lein M., Jung K., Schnorr D., and Loening S.A. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79 (1997) 104-109
39. Stephan C., Stroebel G., Heinau M., et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 104 (2005) 993-1003
40. Ornstein D.K., Smith D.S., Humphrey P.A., and Catalona W.J. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 159 (1998) 1234-1237
41. Arcangeli C.G., Humphrey P.A., Smith D.S., et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51 (1998) 558-564
42. Elgamal A.A., Cornillie F.J., Van Poppel H.P., Van de Voorde W.M., McCabe R., and Baert L.V. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 156 (1996) 1042-1047
43. Pannek J., Rittenhouse H.G., Chan D.W., Epstein J.I., Walsh P.C., and Partin A.W. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 159 (1998) 1238-1242
44. Bangma C.H., Kranse R., Blijenberg B.G., and Schröder F.H. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 157 (1997) 544-547
45. Henricks W.H., England B.G., Giacherio D.A., Oesterling J.E., and Wojno K.J. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer. Am J Clin Pathol 109 (1998) 533-539
46. Lerner S.E., Jacobsen S.J., Lilja H., et al. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 48 (1996) 240-248
47. Li W., Ren Y., Mee V., and Wong P.Y. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer. Clin Biochem 32 (1999) 31-37
48. Morote J., Encabo G., Lopez M.A., and De Torres I.M. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer. BJU Int 83 (1999) 1003-1006
49. Southwick P.C., Catalona W.J., Partin A.W., et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162 (1999) 1346-1351
50. Raaijmakers R., Blijenberg B.G., Finlay J.A., et al. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 171 (2004) 2245-2249
51. Carter H.B., Partin A.W., Luderer A.A., et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49 (1997) 379-384
52. Horninger W., Volgger H., Rogatsch H., et al. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the tyrol prostate specific antigen screening project. J Urol 165 (2001) 1143-1145
53. Morote J., Raventos C.X., Encabo G., Lopez M., and De Torres I.M. Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen. Eur Urol 37 (2000) 456-459
54. Ramos C.G., Carvahal G.F., Mager D.E., Haberer B., and Catalona W.J. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol 162 (1999) 1587-1590
55. Stephan C., Lein M., Jung K., Schnorr D., and Loening S.A. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?[Letter]. J Urol 157 (1997) 1371
56. Lee C.T., and Scardino P.T. Percent free prostate-specific antigen for first-time prostate biopsy. Urology 57 (2001) 594-598
57. Roehl K.A., Antenor J.A., and Catalona W.J. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J Urol 168 (2002) 922-925
58. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
59. Wu J.T., Zhang P., Liu G.H., and Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 12 (1998) 14-19
60. Partin A.W., Brawer M.K., Subong E.N.P., et al. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Diseases 1 (1998) 197-203
61. Wang T.J., Linton H.J., Payne J., et al. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. Hybridoma 18 (1999) 535-541
62. Stamey T.A., and Yemoto C.E. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol 163 (2000) 119-126
63. 1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate 47 (2001) 77-84
64. Jung K., Brux B., Lein M., et al. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. Urology 53 (1999) 1160-1167
65. Zhu L., Leinonen J., Zhang W.M., Finne P., and Stenman U.H. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA. Clin Chem 49 (2003) 97-103
66. Allard W.J., Zhou Z., and Yeung K.K. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem 44 (1998) 1216-1223
67. Jung K., Elgeti U., Lein M., et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?. Clin Chem 46 (2000) 55-62
68. Lein M., Jung K., Elgeti U., et al. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. Eur Urol 39 (2001) 57-64
69. Tanguay S., Begin L.R., Elhilali M.M., Behlouli H., Karakiewicz P.I., and Aprikian A.G. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 59 (2002) 261-265
70. Partin A.W., Brawer M.K., Bartsch G., et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 170 (2003) 1787-1791
71. Lein M., Kwiatkowski M., Semjonow A., et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 170 (2003) 1175-1179
72. Rittenhouse H.G., and Chan D.W. Can complexed PSA be used as a single test for detecting prostate cancer?. Urology 54 (1999) 4-5
73. Stephan C., Jung K., Lein M., Schnorr D., and Loening S.A. Re: complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 164 (2000) 1671-1672
74. Stephan C., Schnorr D., Loening S.A., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399 1059-60
75. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399
76. Zhang W.M., Finne P., Leinonen J., Salo J., and Stenman U.H. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 56 (2000) 267-272
77. Finne P., Zhang W.M., Auvinen A., et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J Urol 164 (2000) 1956-1960
78. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., and Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253-259
79. Mikolajczyk S.D., Song Y., Wong J.R., Matson R.S., and Rittenhouse H.G. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 37 (2004) 519-528
80. Nurmikko P., Vaisanen V., Piironen T., Lindgren S., Lilja H., and Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 46 (2000) 1610-1618
81. Nurmikko P., Pettersson K., Piironen T., Hugosson J., and Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47 (2001) 1415-1423
82. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756-759
83. Peter J., Unverzagt C., Krogh T.N., Vorm O., and Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 (2001) 957-962
84. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 (2001) 6958-6963
85. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017-1025
86. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181-2185
87. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
88. Bangma C.H., Wildhagen M.F., Yurdakul G., Schroder F.H., and Blijenberg B.G. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93 (2004) 720-724
89. Lein M., Semjonow A., Graefen M., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174 (2005) 2150-2153
90. Peyromaure M., Fulla Y., Debre B., and Dinh-Xuan A.T. Pro PSA: a "pro cancer" form of PSA?. Med Hypotheses 64 (2005) 92-95
91. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45 (1995) 729-744
92. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., and Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35 (1998) 275-368
93. Yousef G.M., and Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 22 (2001) 184-204
94. Diamandis E.P., Yousef G.M., Clements J., et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 46 (2000) 1855-1858
95. Lundwall A., Band V., Blaber M., et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 387 (2006) 637-641
96. Kwiatkowski M.K., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52 (1998) 360-365
97. Nam R.K., Diamandis E.P., Toi A., et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18 (2000) 1036-1042
98. Partin A.W., Catalona W.J., Finlay J.A., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54 (1999) 839-845
99. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., and Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57 (1997) 3111-3114
100. Diamandis E.P., Yousef G.M., Luo I., Magklara I., and Obiezu C.V. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11 (2000) 54-60
101. Lövgren J., Rajakoski K., Karp M., Lundwall A., and Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238 (1997) 549-555
102. Takayama T.K., Fujikawa K., and Davie E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272 (1997) 21582-21588
103. Diamandis E.P., Yousef G.M., Petraki C., and Soosaipillai A.R. Human kallikrein 6 as a biomarker of alzheimer's disease. Clin Biochem 33 (2000) 663-667
104. Diamandis E.P., Yousef G.M., Soosaipillai A.R., and Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33 (2000) 579-583
105. Luo L.Y., Grass L., Howarth D.J., Thibault P., Ong H., and Diamandis E.P. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 47 (2001) 237-246
106. Luo L., Bunting P., Scorilas A., and Diamandis E.P. Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. Clin Chim Acta 306 (2001) 111-118
107. Becker C., Piironen T., Kiviniemi J., Lilja H., and Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 46 (2000) 198-206
108. Black M.H., Magklara A., Obiezu C.V., Melegos D.N., and Diamandis E.P. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 45 (1999) 790-799
109. Klee G.G., Goodmanson M.K., Jacobsen S.J., et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 45 (1999) 800-806
110. Becker C., Piironen T., Pettersson K., et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163 (2000) 311-316
111. Magklara A., Scorilas A., Catalona W.J., and Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45 (1999) 1960-1966
112. Haese A., Becker C., Noldus J., et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer. J Urol 163 (2000) 1491-1497
113. Recker F., Kwiatkowski M.K., Piironen T., et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55 (2000) 481-485
114. Haese A., Graefen M., Steuber T., et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 170 (2003) 2269-2273
115. Stamey T.A. Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 47 (2001) 631-634
116. Haese A., Graefen M., Steuber T., et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49 (2001) 101-109
117. Haese A., Graefen M., Becker C., et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 54 (2003) 181-186
118. Stephan C., Jung K., Nakamura T., Yousef G.M., Kristiansen G., and Diamandis E.P. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 13 (2006) 238-243
119. Stephan C., Jung K., Soosaipillai A., et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 96 (2005) 521-527
120. Vaisanen V., Eriksson S., Ivaska K.K., Lilja H., Nurmi M., and Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 50 (2004) 1607-1617
121. Saedi M.S., Hill T.M., Kuus R.K., et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 44 (1998) 2115-2119
122. Wang T.J., Linton J., Rittenhouse H.G., et al. The development of dual monoclonal antibody immunoassay for accurate measurement of serum human kallikrein 2 complex (chK2). J Urol [Suppl] 163 (2000) 180A
123. Mikolajczyk S.D., Millar L.S., Marker K.M., et al. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res 59 (1999) 3927-3930
124. Yousef G.M., Obiezu C.V., Luo L.Y., Black M.H., and Diamandis E.P. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 59 (1999) 4252-4256
125. Dong Y., Bui L.T., Odorico D.M., et al. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocr Relat Cancer 12 (2005) 875-889
126. Obiezu C.V., Shan S.J., Soosaipillai A., et al. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 51 (2005) 1432-1442
127. Xi Z., Klokk T.I., Korkmaz K., et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64 (2004) 2365-2370
128. Day C.H., Fanger G.R., Retter M.W., et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 21 (2002) 7114-7120
129. Diamandis E.P., Okui A., Mitsui S., et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62 (2002) 295-300
130. Nakamura T., Scorilas A., Stephan C., Jung K., Soosaipillai A.R., and Diamandis E.P. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 63 (2003) 6543-6546
131. Stephan C., Meyer H.A., Cammann H., Nakamura T., Diamandis E.P., and Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 387 (2006) 801-805
132. Yoshida S., Taniguchi M., Suemoto T., et al. cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta 1399 (1998) 225-228
133. Yousef G.M., Magklara A., and Diamandis E.P. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69 (2000) 331-341
134. Yousef G.M., Scorilas A., and Diamandis E.P. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 63 (2000) 88-96
135. Yousef G.M., Chang A., and Diamandis E.P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275 (2000) 11891-11898
136. Yousef G.M., Magklara A., Chang A., Jung K., Katsaros D., and Diamandis E.P. Cloning of a new member of the human kallikrein gene family, klk14, which is down-regulated in different malignancies. Cancer Res 61 (2001) 3425-3431
137. Yousef G.M., Scorilas A., Jung K., Ashworth L.K., and Diamandis E.P. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 276 (2001) 53-61
138. Stephan C., Yousef G.M., Scorilas A., et al. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostate tissue. J Urol 169 (2003) 361-364
139. Shaw J.L., Grass L., Sotiropoulou G., and Diamandis E.P. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin Biochem 40 (2007) 104-110